JP Morgan Chase
CAPR icon

JP Morgan Chase’s Capricor Therapeutics CAPR Stock Holding History

JP Morgan Chase’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-150,000
Closed -$1.49M – 7417
2025
Q2 		$1.49M Buy
+150,000
New +$1.58M ﹤0.01% 4128

Other funds holding CAPR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

JP Morgan Chase's CAPR Position: Q1 2026 in Review

JP Morgan Chase reduced its Capricor Therapeutics (CAPR) stake by 6.9% in Q1 2026, selling an estimated $680K and leaving 343,613 shares worth $9.54M. The position accounts for ﹤0.01% of the portfolio, ranked #2722.

JP Morgan Chase first reported a position in CAPR in Q2 2017 and has held it in 14 quarters since. The position peaked at $10.7M in Q4 2025. 177 funds tracked by Wall St. Rank hold CAPR as of Q1 2026.

  • JP Morgan Chase held 343,613 shares of Capricor Therapeutics worth $9.54M as of Q1 2026.
  • JP Morgan Chase sold 25,521 Capricor Therapeutics shares in Q1 2026, an estimated $680K.
  • Capricor Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #2722 holding.
  • JP Morgan Chase first reported a position in Capricor Therapeutics in Q2 2017 and has held it in 14 quarters since.
  • JP Morgan Chase's Capricor Therapeutics position peaked at $10.7M in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.